Recent Updates
Recently added Catalysts
MDXG Positive Sentiment Score: 82/100

MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue

Key Takeaway: MiMedx Group, Inc. (MDXG) has emphasized a New York Times feature on the advantages of placental allografts for treating hard-to-heal wounds. The article discusses the opportunity for mothers to donate placental tissue after C-sections, which MIMEDX utilizes in its products. CEO Joseph H. Capper noted his satisfaction with the increased visibility of this treatment area, despite the company not being specifically named in the article. Two patients featured in the article have successfully recovered with the help of MIMEDX products, showcasing their effectiveness.

Market Sentiment Analysis

POSITIVE FACTORS

  • The New York Times article highlights the substantial benefits of placental allografts.
  • MIMEDX's products have shown positive outcomes in patient recoveries.
  • CEO Joseph H. Capper expresses enthusiasm about the increased awareness due to media coverage.

Full Press Release Details

MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds, which was published in today’s New York Times: “Her Face Was Unrecognizable After an Explosion. A Placenta Restored It.”
The author underscored the benefits of placental allografts for a variety of wound care and surgical procedures and brought attention to the largely unknown opportunity for a mother to donate her nutrient rich placenta after a healthy C-section delivery. MIMEDX uses this source material to produce the majority of its product offerings today.
Commenting on the article, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, “We were delighted to see attention called to this area of patient care and to contribute to this important piece. While MIMEDX is not mentioned by name, two individuals from our “Patient Story” series, Marcella and Phyllis, are prominently featured in the article, showcasing their remarkable recoveries. In both cases our products played a central role.”
Mr. Capper concluded, “We believe this article and the recently-published Nature – Scientific Reports publication will increase awareness about the unique scientific properties and growing clinical use of placental-derived products to treat patients with chronic and other hard-to-heal wounds.”
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Frequently Asked Questions

What is the focus of MIMEDX's recent article?

The article highlights placental allografts for treating hard-to-heal wounds.

How are placental allografts beneficial?

They offer significant advantages for various wound care and surgical procedures.

What role do mothers play in placental donation?

Mothers can donate their nutrient-rich placenta after a healthy C-section.

Who featured in the New York Times article?

Marcella and Phyllis from MIMEDX's 'Patient Story' series are prominently displayed.

What is MIMEDX's vision?

MIMEDX aims to be the leading global provider of healing solutions through innovation.

Last updated: Oct 8, 2024